Results 51 to 60 of about 57,133 (184)

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Magnetite Micro/Nanorobots for Efficient Targeted Alleviation of Inflammatory Bowel Disease

Advanced Science, EarlyView.
Improved reactive oxygen species scavenging capacities of functionalized micro/nanorobots (MNRs) are useful for the treatment of inflammatory bowel disease (IBD). MNRs can break the harmful bacteria in IBD, thereby eliminating inflammation and restoring the intestinal barrier function.
Ying Feng, Yang Liu, Linlin Liu, Qian Yang, Miao An, Huaming Yang   +5 more
wiley   +1 more source

Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. [PDF]

, 2016
Commercial dietary supplements are marketed as a panacea for the morbidly obese seeking sustainable weight-loss. Unfortunately, many claims cited by supplements are unsupported and inadequately regulated.
Bodzin, Adam S, Busuttil, Ronald W, Lunsford, Keri E, Reino, Diego C, Wang, Hanlin L   +4 more
core   +1 more source

The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis

Advanced Science, EarlyView.
This review summarizes recent advances in understanding the immune microenvironment's role in fibrosis, focusing on phenotypic/functional alterations of immune cells and their dynamic interactions with other cellular constituents within tissues. The authors further explore therapeutic opportunities and challenges in targeting immune microenvironment ...
Xiangqi Chen, Chuan Wu, Fei Tang, Jingyue Zhou, Li Mo, Yanping Li, Jinhan He   +6 more
wiley   +1 more source

Autoimmune hepatitis in childhood [PDF]

Clinical Liver Disease, 2014
There are three clinical patterns of AIH presentation: an acute pattern (rarely fulminant, particularly in AIH2) in approximately 50%, an insidious pattern (progressive fatigue, relapsing jaundice, headache, anorexia, and amenorrhea) in approximately 50%, and complications of portal hypertension (splenomegaly and bleeding varices) in approximately 10%.
Giorgina Mieli-Vergani, Diego Vergani
openaire   +3 more sources

The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis [PDF]

, 2016
Although necrosis and necroinflammation are central features of many liver diseases, the role of programmed necrosis in the context of inflammation-dependent hepatocellular death remains to be fully determined.
Andreas E. Kremer, Andreas Linkermann, Babon, Cai, Christin Dewitz, Christoph Becker, Christopher Poremba, Claudia Günther, Deutsch, Dusheiko, Emma J. Petrie, Gui-Wei He, James M. Murphy, Kang, Kerstin Amann, Ma, Manns, Marinescu, Markus F. Neurath, Peter Vandenabeele, Pine, Siebler, Stefan Krautwald, Stefan Wirtz, Ulrike Schleicher   +24 more
core   +1 more source

Autoimmune hepatitis on the rise

Journal of Hepatology, 2014
1st Dept. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GermanySee Article, pages 612–617Autoimmune hepatitis (AIH) is considered a rare disease. Theincidence and prevalence of AIH has been assessed in only twostudies on a population based level [1,2].
Christoph Schramm, Ansgar W. Lohse
openaire   +2 more sources

Eltrombopag for the treatment of immune thrombocytopenia: The aegean region of Turkey experience [PDF]

, 2015
Objective: Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by transient or persistent decrease of the platelet count to less than 100x109/L. Although it is included in a benign disease group, bleeding complications may be mortal.
Alacacıoğlu, İ., Arslan, Ö., Bilgir, O., Bolaman, Z., Büyükkeçeci, F., Ceylan, C., Gökgöz, Z., Görgün, G., Kabukçu, Sibel, Kadıköylü, G., Kahraman, S., Keskin, A., Kiper, H.D., Payzın, B., Saydam, G., Sevindik, Ö.G., Tombuloğlu, M., Vural, F., Çağlıyan, G.A., Özcan, M.A., Özdemirkıran, F., Şahin, F.   +21 more
core   +3 more sources